Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT04412473
NCT04412473UnknownNot Applicable

COVID-19 Respiratory Distress and Antithrombotic Drugs inSubject's Habits

University Hospital, Strasbourg, France1 site in 1 country1,000 target enrollmentStarted: April 30, 2020Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
1,000
Locations
1
Primary Endpoint
Analysis of Respiratory Distress and Antithrombolytic Therapy in Patients with covid19
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Current management of VID-19 consists of oxygen support without specific treatment. Hospitalization may suddenly require delayed resuscitation. This evolution corresponds to an atypical acute respiratory distress syndrome (ARDS), the mechanism of which is poorly understood and difficult to predict. The general pathophysiology of ARDS, the vascular tropism of SARS-Cov2, the description of coagulopathy and numerous pulmonary artery thromboses in resuscitation and the encouraging investigation of antithrombotics in general ARDS

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Major Subject (≥18 years)
  • •Subject hospitalised in HUS or GHRMSA for COVID-19
  • •The diagnosis COVID-19 confirmed by smear or evoked by CT scan or chest X-ray without a differential diagnosis retained in the medical record
  • •Subjects who, after being informed, do not wish to have their data reused for the purposes of this research

Exclusion Criteria

  • •Subject who expressed opposition to participating in the study
  • •Subject under guardianship or trusteeship
  • •Subject under safeguard of justice
  • •Patient hospitalized in a geriatric service or in a ward not labeled COVID (surgery, oncology,...) or in a short-term hospitalization unit without transfer to another service.
  • •Serious patient on admission to the emergency room and recused from resuscitation.

Outcomes

Primary Outcomes

Analysis of Respiratory Distress and Antithrombolytic Therapy in Patients with covid19

Time Frame: 1 month

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
University Hospital, Strasbourg, France
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Phase 3
Study Of Oxygen requirement in COVID-19 Patients in IC
CTRI/2022/01/039725il
Completed
Phase 4
Handling Oxygenation Targets in COVID-19Hypoxemic Respiratory FailureOxygen Toxicity
NCT04425031Aalborg University Hospital726
Completed
Not Applicable
Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress SyndromeSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
NCT04725084Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer355
Terminated
Not Applicable
AnaConDa-therapy in COVID-19 PatientsCOVID-19SARS CoV-2
NCT05586126Jeroen Bosch Ziekenhuis42
Terminated
Phase 3
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)COVID-19
NCT05605093University of Minnesota602